Avadel Pharmaceuticals plc Ordinary Share
AVDLAvadel Pharmaceuticals plc is a specialty pharmaceutical company focused on the development and commercialization of innovative medicines for the treatment of chronic diseases, primarily targeting sleep and neurological disorders. The company emphasizes leveraging its proprietary drug delivery technologies to improve patient outcomes and address unmet medical needs.
Company News
Avadel Pharmaceuticals announced the mailing of a proxy statement regarding its proposed acquisition by Alkermes, with scheme and extraordinary general meetings scheduled for January 12, 2026, to vote on the transaction.
Law firm investigating potential securities law violations and fiduciary duty breaches for several companies involved in mergers and acquisitions.
Avadel Pharmaceuticals reported strong Q2 2025 financial results, with GAAP revenue of $68.1 million, exceeding analyst expectations by 10.9%. The company achieved its first profitable quarter since LUMRYZ's launch, driven by increased patient adoption and strong commercial performance in narcolepsy treatment.
Harrow (HROW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
